We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.46B
AUM Growth
-$440K
Cap. Flow
-$163M
Cap. Flow %
-11.2%
Top 10 Hldgs %
60.09%
Holding
84
New
10
Increased
23
Reduced
32
Closed
17
Avg Time Held Equity + Options
1.7 years
Top 10 Avg Time Held Equity + Options
1.2 years
Top 20 Avg Time Held Equity + Options
1.3 years
Avg Time Held Equity only
1.7 years
Top 10 Avg Time Held Equity only
1.2 years
Top 20 Avg Time Held Equity only
1.4 years

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$24.1M
2
ZIMV icon
ZimVie
ZIMV
+$23.4M
3
FTRE icon
Fortrea Holdings
FTRE
+$10.8M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$10.2M
5
BHC icon
Bausch Health
BHC
+$10.1M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$44.6M
2
UTHR icon
United Therapeutics
UTHR
+$35.3M
3
NTRA icon
Natera
NTRA
+$34.8M
4
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$26M
5
NVO icon
Novo Nordisk
NVO
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 89.3%
2 Miscellaneous 10.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GSK icon
1
GSK
GSK
$99.2B
$166M 11.36%
4,057,206
+589,126
+17% +$24.1M
2018 Q1
26 quarters
QQQ icon
2
PUT
Invesco QQQ Trust
QQQ
$475B
$122M 8.34%
249,600
-36,000
-13% -$17M
2023 Q1
6 quarters
NTRA icon
3
Natera
NTRA
$56.7B
$110M 7.57%
870,193
-303,301
-26% -$34.8M
2022 Q2
9 quarters
VERA icon
4
Vera Therapeutics
VERA
$2.01B
$90.6M 6.21%
2,050,157
+6,943
+0.3% +$263K
2022 Q3
8 quarters
INSM icon
5
Insmed
INSM
$21B
$79.5M 5.45%
1,089,404
-66,184
-6% -$4.88M
2024 Q2
1 quarter
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$1.15B
$79M 5.41%
4,105,313
+491,682
+14% +$10.2M
2022 Q2
9 quarters
RVTY icon
7
Revvity
RVTY
$17B
$60M 4.11%
469,692
+18,110
+4% +$2.13M
2021 Q3
12 quarters
INSP icon
8
Inspire Medical Systems
INSP
$1.99B
$58.3M 3.99%
276,270
-256,741
-48% -$44.6M
2023 Q2
5 quarters
TEVA icon
9
Teva Pharmaceutical Industries Limited
TEVA
$48.4B
$58.3M 3.99%
3,234,638
-1,485,822
-31% -$26M
2020 Q3
16 quarters
CYH icon
10
Community Health Systems
CYH
$406M
$53.3M 3.65%
8,776,455
+738,985
+9% +$3.62M
2020 Q4
15 quarters
TECH icon
11
Bio-Techne
TECH
$11.4B
$53M 3.63%
663,573
+120,529
+22% +$9.06M
2022 Q4
7 quarters
HCA icon
12
HCA Healthcare
HCA
$99.3B
$52.5M 3.59%
129,084
-6,396
-5% -$2.34M
2023 Q1
6 quarters
UTHR icon
13
United Therapeutics
UTHR
$22.9B
$46.9M 3.21%
130,949
-104,402
-44% -$35.3M
2020 Q2
17 quarters
SPY icon
14
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$806B
$34.4M 2.36%
60,000
+29,200
+95% +$16.1M
2023 Q1
6 quarters
ZIMV icon
15
DELISTED
ZimVie
ZIMV
$32.9M 2.25%
2,070,780
+1,303,121
+170% +$23.4M
2023 Q4
3 quarters
HQY icon
16
HealthEquity
HQY
$7.61B
$26.1M 1.79%
319,078
-94,453
-23% -$7.29M
2023 Q3
4 quarters
RGEN icon
17
Repligen
RGEN
$11.1B
$24.3M 1.67%
163,593
-30,698
-16% -$4.4M
2021 Q1
14 quarters
VTRS icon
18
Viatris
VTRS
$21.4B
$20M 1.37%
1,726,354
+397,072
+30% +$4.58M
2024 Q1
2 quarters
PTGX icon
19
Protagonist Therapeutics
PTGX
$8.33B
$20M 1.37%
445,204
-60,632
-12% -$2.45M
2023 Q2
5 quarters
CLDX icon
20
Celldex Therapeutics
CLDX
$2.16B
$19.2M 1.32%
564,902
-68,113
-11% -$2.6M
2021 Q4
11 quarters
IONS icon
21
Ionis Pharmaceuticals
IONS
$7.14B
$18.9M 1.29%
471,355
+14,474
+3% +$673K
2021 Q2
13 quarters
VRDN icon
22
Viridian Therapeutics
VRDN
$2.16B
$15.7M 1.08%
691,232
+123,745
+22% +$2.02M
2023 Q3
4 quarters
MNKD icon
23
MannKind Corp
MNKD
$977M
$12.5M 0.86%
1,992,504
-264,448
-12% -$1.52M
2024 Q1
2 quarters
BHC icon
24
Bausch Health
BHC
$2.36B
$12.5M 0.86%
+1,530,914
New +$10.1M
2024 Q3
0 quarters
TVTX icon
25
Travere Therapeutics
TVTX
$4.68B
$12.2M 0.83%
869,913
-221,252
-20% -$2.31M
2024 Q1
2 quarters
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Eversept Partners held 84 positions worth $1.46B, down 0.03% from $1.46B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Eversept Partners withdrew a net $163M in Q3 2024, closing 17 positions and reducing 32 holdings. Its most notable exit was Novo Nordisk, an estimated $21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 89% a quarter earlier, followed by Miscellaneous.

Against the trend, Eversept Partners opened a new position in Fortrea Holdings worth $9.16M.

  • Eversept Partners's largest Q3 2024 buy was Fortrea Holdings: 457,967 shares worth $9.16M.
  • Eversept Partners added most to GSK in Q3 2024, an estimated $24.1M increase.
  • Eversept Partners's biggest Q3 2024 reduction was Inspire Medical Systems, cutting an estimated $44.6M.
  • Eversept Partners fully exited Novo Nordisk in Q3 2024, selling an estimated $21M.
  • Eversept Partners's ten largest holdings make up 60% of its $1.46B portfolio in Q3 2024.
  • Eversept Partners opened 10 new positions and closed 17 in Q3 2024.
  • Eversept Partners's portfolio value fell 0.03% quarter-over-quarter to $1.46B.

Based on Eversept Partners's 13F filing for Q3 2024, filed 14 Nov 2024.